US FDA warns Vista Pharmaceuticals about Telangana plant

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Food and drug administration

Vista Pharmaceuticals Limited’s plant in Nalgonda, Telangana is in a state of disrepair according to the US Food and Drug Administration (FDA).

In a warning letter​ published this week the US regulator said inspectors who visited the facility last September discovered corroded production equipment.

They also criticised Vista for failing to examine if metal found in pills made at the site was there as a result of the poor condition of the technology.

The FDA also said Vista had not validated production processes for a vasodilator called isoxsuprine hydrochloride previously made at the facility, several batches of which were shipped to the US between 2014 and 2016.

The agency also raised concerns that Vista’s isoxsuprine hydrochloride tablets “appear to be identical, related, or similar (IRS) to Vasodilan tablets, which are the subject of pending Drug Efficacy Study Implementation (DESI) proceeding 6403​.”

DESI review

US approval for Vasodilan was withdrawn in 2009​. The drug is still being reviewed under the US DESI programme, which required the FDA to conduct a retrospective evaluation of the effectiveness of the drugs approved between 1938 and 1962.  

The FDA said: “Since the withdrawal of the Vasodilan application, FDA has been made aware of adverse event cases that may be associated with use of isoxsuprine hydrochloride.

While it is generally FDA’s policy to allow drug products subject to an ongoing DESI proceeding to remain on the market during the pendency of the proceeding, if potential safety issues arise or other violations of the FD&C Act are present, we may take appropriate action​.”

Related news

Show more

Related products

show more

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 07-Dec-2021 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

Flexibility and capability in pre-filled syringes

Flexibility and capability in pre-filled syringes

Curia | 15-Nov-2021 | Technical / White Paper

Pre-filled syringes have risen in popularity in recent years but the pandemic’s impact on drug development, manufacturing and patient care has created...

LACTIUM®: dairy bioactive to soothe your pet

LACTIUM®: dairy bioactive to soothe your pet

Ingredia | 12-Oct-2021 | Infographic

Lactium® gives you the chance to better meet your pet’s needs for a more harmonious life together. Lactium® acts on the brain and has no side-effects,...

Related suppliers

Follow us


View more